AUTHORS
Kieran Sahasrabudhe, MD, Moudar Jano, MD2, Bianca Barredo, BS3, Lauren G. Banaszak, MD4, Deedra Nicolet, MS5, Michael Walker6, Prem Geeta Torlapati7, Justice Ameyi, M.S.8, Krzysztof Mrózek, MD, PhD9, Alice Scott Mims, MD10, Ann-Kathrin Eisfeld, MD11, Michael Jamie Hochman, MD12, Laneisha Maldonado Jaime, MD13, Jesus D Gonzalez-Lugo, MD14, Charles Foucar, MD15, Jessica Lewis-Gonzalez, PharmD, BCOP16, Alexander Joseph Ambinder, MD, MPH17
AFFILIATIONS
1 University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
2 University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
3 University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
4 University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
5 The Ohio State University Comprehensive Cancer Center, Columbus, United States
6 The Ohio State University Comprehensive Cancer Center, Columbus, United States
7 The Ohio State University Comprehensive Cancer Center, Columbus, United States
8 The Ohio State University Comprehensive Cancer Center, Columbus, United States
9 The Ohio State University Comprehensive Cancer Center, Columbus, United States
10 The Ohio State University Comprehensive Cancer Center, Columbus, United States
11 The Ohio State University Comprehensive Cancer Center, Columbus, United States
12 Emory Winship Cancer Institute, Atlanta, United States
13 Emory Winship Cancer Institute, Atlanta, United States
14 University of Kansas Cancer Center, Kansas City, United States
15 University of New Mexico Comprehensive Cancer Center, Albuquerque, United States
16 University of New Mexico Comprehensive Cancer Center, Albuquerque, United States
17 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
ABSTRACT
Introduction:
Frontline therapy with HMA+ven has become standard of care for newly diagnosed (ND) pts with AML deemed ineligible for intensive chemotherapy (IC). Preliminary results of the Phase 3 PARADIGM trial show HMA+ven associated with superior overall response rate and event-free survival compared to IC in pts with ND AML age ≥18 (yrs) deemed eligible for IC. The efficacy of IC vs HMA+ven in specific molecular subgroups of AML is an area of ongoing investigation. Mutations in KRAS or NRAS are known to negatively impact prognosis in pts treated with HMA-based therapies. Mutations in additional genes in the RAS signaling pathway, CBL and PTPN11, have also been associated with adverse outcome in previous retrospective analyses. The decision to use IC vs HMA+ven has traditionally been most relevant in pts age ≥60 yrs since the majority of younger pts are eligible for IC. The relative efficacy of IC vs HMA+ven in pts age ≥60 yrs with RAS signaling pathway mutations remains undefined. Here we sought to address this question in a real-world cohort of pts treated at six U.S. academic medical centers.
Methods:
This multicenter retrospective cohort study included pts treated at six academic institutions from the US Myeloid Malignancy Association for Retrospective Research Outcomes Working Group (MARROW). Pts age ≥60 yrs with ND AML harboring mutations in KRAS, NRAS, CBL, or PTPN11 were included if they received frontline therapy with either IC or HMA+ven. IC included cytarabine and an anthracycline given as 7+3 or liposomal cytarabine+daunorubicin (CPX-351). Pts with core-binding factor AML, FLT3 mutations and BCR/ABL1 fusions were excluded to mirror disease features of pts age ≥60 yrs included in the PARADIGM trial. Baseline characteristics, complete response rate (CR), relpase-free survival (RFS), and overall survival (OS) were compared for pts receiving IC vs HMA+ven.
Results:
Among 163 pts analyzed, 107 were treated with IC and 56 with HMA+ven. KRAS mutations were present in 44 (27%) pts, NRAS mutations in 83 (51%), CBL mutations in 22 (13%) and PTPN11 mutations in 37 (23%) pts. Pt ages ranged from 60 to 87 yrs (median, 67). Pts in the HMA+ven arm were older than pts in the IC arm (median, 74 vs 65 yrs, p<0.001), and more of them were men (80% vs 63%, p=0.02). There were no significant differences between the treatment arms in ECOG performance status (PS), race, baseline blood and bone marrow blast percentages. Pts in the IC arm had more favorable ELN 2022 risk stratification than those in the HMA+ven arm (23% favorable, 15% intermediate, 62% adverse vs 4% favorable, 4% intermediate, 92% adverse, p<0.001). There was no significant difference in ELN 2024 risk stratification between the treatment arms. The most common co-mutations in the overall cohort were in the ASXL1 (32%), TET2 (25%), RUNX1 (22%), NPM1 (17%) and SRSF2 (17%) genes. TP53 mutations were present in 4% of pts. Twenty-five pts (23%) in the IC arm underwent allogeneic stem cell transplant vs 6 pts (11%) in the HMA+ven arm (p=0.06).
There was no significant difference in OS between IC vs HMA+ven (median 10.8 vs 8 months (mos), p=0.10). On multivariable analysis (MVA) for OS, ECOG PS of 2-3 was associated with inferior OS compared to PS 0-1 (HR 2.72, p<0.001) and transplant was associated with superior OS (HR 0.25, p<0.001). There was no significant difference in CR rates (48% vs 41%, p=0.51) or RFS (median 9.6 vs 12 mos, p=0.7) between the IC and HMA+ven arms. On MVA for RFS, KRAS mutations (HR 1.92, p=0.02) and ECOG PS 2-3 vs 0-1 (HR 2.47, p=0.01) were associated with inferior and transplant with superior RFS (HR 0.37, p=0.008). A subgroup analysis of pts with KRAS and/or NRAS mutations (n=119) found no significant difference in CR, RFS or OS between the IC (n=81) and HMA+ven (n=38) arms with CR 51% vs 39% (p=0.33), median RFS 10.8 vs 10.7 mos (p=0.89), and median OS 10.8 vs. 8.4 mos (p=0.22).
Conclusion:
This real-world analysis showed no significant differences in CR rate, RFS or OS in pts age ≥60 yrs with ND AML harboring RAS pathway mutations treated with IC vs HMA+ven. Pt performance status, disease characteristics, and receipt of transplant were more strongly predictive of OS and RFS than intensity of frontline therapy. OS was suboptimal with median OS <1yr regardless of frontline treatment received, which highlights the need for ongoing development of novel therapies to improve outcomes in older pts with AML harboring RAS pathway mutations.
DISCLOSURES
Kieran Sahasrabudhe, MD: No relevant conflicts of interest to declare.